Navigate Up

UPMC/University of Pittsburgh Schools of the Health Sciences
For Journalists
Senior Director
Telephone: 412-586-9764

Want to Make an Appointment or Need Patient Information?

Contact UPMC at
1-800-533-UPMC (8762).

Go to Find a Doctor to search for a UPMC doctor.​

University of Pittsburgh Schools of the Health Sciences

Pitt-led Study Examines Cost-Effectiveness of Adult Pneumonia Vaccines

PITTSBURGH, Feb. 22, 2012 – A newly approved vaccine to prevent pneumonia in adults might prevent more illness and be more economical than the vaccine currently in use, according to a study led by researchers at the University of Pittsburgh School of Medicine. The findings appear in the February 22 issue of Journal of the American Medical Association.

The currently used vaccine, 23-valent pneumococcal polysaccharide vaccine (PPSV23), has been recommended for prevention of invasive pneumococcal disease (IPD) since 1983. IPD occurs when the pneumococcus bacteria gets inside normally sterile parts of the body, leading to sepsis, meningitis and other illnesses. The other and more common type of pneumococcal disease is nonbacteremic pneumococcal pneumonia (NPP), and it’s not clear how well the current vaccine prevents this. NPP affects hundreds of thousands of people in the U.S. every year. It is hoped that the new vaccine, 13-valent pneumococcal conjugate vaccine (PCV13), prevents NPP, and the FDA recently approved the use of PCV13 in adults aged 50 and older on the condition that further studies show it is effective against this illness.

Lead author, Kenneth J. Smith, M.D., M.S., of the University of Pittsburgh School of Medicine, and  colleagues conducted a study to estimate the efficacy and cost-effectiveness of pneumococcal vaccination strategies among adults 50 years of age and older. Using various modeling techniques, simulations were performed in hypothetical groups of U.S. 50-year-olds using data from the Centers for Disease Control and Prevention Active Bacterial Core surveillance, the National Hospital Discharge Survey, the Nationwide Inpatient Sample, and the National Health Interview Survey.

With no vaccination, the estimated lifetime risk from age 50 and older for hospitalized NPP was 9.3 percent, for IPD it was 0.86 percent, and for death due to pneumococcal disease it was 1.8 percent. Among the different vaccination strategies, PPSV23 was estimated to prevent more IPD than strategies using only PCV13, and strategies using two scheduled PCV13 doses were estimated to prevent more NPP.

Current recommendations call for PPSV23 to be given at age 65 and at younger ages if co-existing illnesses are present. The researchers found that substituting the newer vaccine under the current recommendations would be more effective at preventing disease and cost $28,900 per quality-adjusted life year (QALY) gained, less than the $34,600 per QALY gained using PPSV23.

“There are no absolute criteria for cost-effectiveness, but it’s clear that strategies using the new adult vaccine are worth a closer look,” Dr. Smith said.

The authors noted that the results of the study are limited because of a lack of evidence about the effectiveness of PCV13 against NPP and that data from ongoing clinical trials and more research into the indirect effects of childhood PCV13 on adult pneumococcal disease rates could strengthen this study’s results.

Collaborators on the study were Angela R. Wateska, M.P.H.; Mary Patricia Nowalk, Ph.D., R.D.; Mahlon Raymund, Ph.D.; and Richard K. Zimmerman, M.D., M.P.H., all of the University of Pittsburgh School of Medicine; and J. Pekka Nuorti, M.D., D.Sc., of the University of Tampere, Tampere, Finland.

The study was supported by the National Institute of Allergy and Infectious Diseases.

UPMC | Affiliated with the University of Pittsburgh Schools of the Health Sciences Supplemental content provided by Healthwise, Incorporated. To learn more, visit

For help in finding a doctor or health service that suits your needs, call the UPMC Referral Service at 412-647-UPMC (8762) or 1-800-533-UPMC (8762). Select option 1.

UPMC is an equal opportunity employer. UPMC policy prohibits discrimination or harassment on the basis of race, color, religion, ancestry, national origin, age, sex, genetics, sexual orientation, gender identity, marital status, familial status, disability, veteran status, or any other legally protected group status. Further, UPMC will continue to support and promote equal employment opportunity, human dignity, and racial, ethnic, and cultural diversity. This policy applies to admissions, employment, and access to and treatment in UPMC programs and activities. This commitment is made by UPMC in accordance with federal, state, and/or local laws and regulations.

Medical information made available on is not intended to be used as a substitute for professional medical advice, diagnosis, or treatment. You should not rely entirely on this information for your health care needs. Ask your own doctor or health care provider any specific medical questions that you have. Further, is not a tool to be used in the case of an emergency. If an emergency arises, you should seek appropriate emergency medical services.

Pittsburgh, PA, USA |